Veeva Systems Dossier
|
SectorHealth Care IndustryHealth Care Technology Beta (adjusted)0.94 Intrinsic Value $229.41median of 6 methods · middle span $166-$308based on filings through 31 Jul 2026 Market Price $285.45Price as of 30 Sep 2026 OvervaluedIntrinsic value is 20% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $46.2B Shares Outstanding 165.8M diluted Moat Rating Wide Next Earnings Date25 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Veeva entered the second half of fiscal 2027 with strong operating momentum: fiscal second-quarter revenue increased 18% and subscription revenue increased 16%, results exceeded guidance, and management raised its full-year outlook. Vault CRM adoption is strengthening, with more than 180 customers live and 12 of the top 20 biopharmas committed globally, while Falcon and Vault AI create additional long-term optionality. However, the issuer-reported share price of $276.69 already discounts substantial execution. The resulting risk-reward supports a Hold pending evidence that CRM migrations and agentic products can sustain upper-teen growth. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$165.00 Mean target$244.14 High · most bullish analyst$350.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $165.0023% Revenue falls below the fiscal third-quarter guidance floor, subscription growth decelerates below 12%, or Falcon adoption fails to progress beyond the five disclosed early adopters. Slower customer decisions, competitive pressure, or product and security issues would reduce growth expectations and support a $220 downside scenario. Base CaseCentral scenario $244.1457% Matches the consensus meanVeeva delivers fiscal third-quarter revenue within its $932 million to $935 million guidance range and fiscal 2027 revenue near the $3.682 billion to $3.687 billion range. Vault CRM deployments and R&D and Quality adoption sustain growth, but early-stage Falcon commercialization and the elevated starting share price limit upside. Bull CaseUpside scenario $350.0020% Revenue growth remains in the upper teens, the 12 top-20 Vault CRM commitments convert into successful deployments, and Falcon moves beyond its five early adopters into meaningful commercial adoption. Strong execution and increased confidence in durable AI-enabled growth support multiple resilience and a $350 scenario target. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |